Literature DB >> 32931777

Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression.

Raju Khatri1, Natasha Kulick1, Rebecca J B Rementer1, John K Fallon2, Craig Sykes1, Amanda P Schauer1, Melina M Malinen1, Merrie Mosedale1, Paul B Watkins1, Angela D M Kashuba1, Kim A Boggess3, Philip C Smith2, Kim L R Brouwer1, Craig R Lee4.   

Abstract

Pregnancy-related hormones (PRH) have emerged as key regulators of hepatic cytochrome P450 (CYP) enzyme expression and function. The impact of PRH on protein levels of CYP3A4 and other key CYP enzymes, and the metabolism of nifedipine (a CYP3A4 substrate commonly prescribed during pregnancy), was evaluated in primary human hepatocytes. Sandwich-cultured human hepatocytes (SCHH) from female donors were exposed to PRH (estradiol, estriol, estetrol, progesterone, and cortisol), individually or in combination as a cocktail. Absolute protein concentrations of twelve CYP isoforms in SCHH membrane fractions were quantified by nanoLC-MS/MS, and metabolism of nifedipine to dehydronifedipine in SCHH was evaluated. PRH significantly increased CYP3A4 protein concentrations and nifedipine metabolism to dehydronifedipine in a concentration-dependent manner. CYP3A4 mRNA levels in hepatocyte-derived exosomes positively correlated with CYP3A4 protein levels and dehydronifedipine formation in SCHH. PRH also increased CYP2B6, CYP2C8 and CYP2A6 levels. Our findings demonstrate that PRH increase nifedipine metabolism in SCHH by inducing CYP3A4 expression and alter expression of other key CYP proteins in an isoform-specific manner, and suggest that hepatocyte-derived exosomes warrant further investigation as biomarkers of hepatic CYP3A4 metabolism. Together, these results offer mechanistic insight into the increases in nifedipine metabolism and clearance observed in pregnant women.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytochrome P450; Estradiol; Exosomes; Hepatic metabolism; Hypertension; Nifedipine; Pregnancy; Progesterone; Targeted proteomics

Mesh:

Substances:

Year:  2020        PMID: 32931777      PMCID: PMC7750305          DOI: 10.1016/j.xphs.2020.09.013

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  54 in total

1.  Concept: The Use of Targeted Immunoaffinity Proteomics for Routine Assessment of In Vitro Enzyme Induction.

Authors:  Caroline MacLean; Frederik Weiß; Oliver Poetz; Thomas Ebner
Journal:  J Pharm Sci       Date:  2017-08-01       Impact factor: 3.534

2.  Pregnancy decreases rat CYP1A2 activity and expression.

Authors:  Alysa A Walker; Leslie Dickmann; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2010-10-04       Impact factor: 3.922

3.  Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Jashvant D Unadkat
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

Review 4.  Clinical practice. Chronic hypertension in pregnancy.

Authors:  Ellen W Seely; Jeffrey Ecker
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

5.  Pregnane X receptor regulates the AhR/Cyp1A1 pathway and protects liver cells from benzo-[α]-pyrene-induced DNA damage.

Authors:  Hongmei Cui; Xinsheng Gu; Jingshu Chen; Ying Xie; Sui Ke; Jing Wu; Andrei Golovko; Benjamin Morpurgo; Chunhong Yan; Timothy D Phillips; Wen Xie; Jianyuan Luo; Zhijun Zhou; Yanan Tian
Journal:  Toxicol Lett       Date:  2017-04-18       Impact factor: 4.372

6.  Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Authors:  Sumio Ohtsuki; Olaf Schaefer; Hirotaka Kawakami; Tae Inoue; Stephanie Liehner; Asami Saito; Naoki Ishiguro; Wataru Kishimoto; Eva Ludwig-Schwellinger; Thomas Ebner; Tetsuya Terasaki
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

7.  Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells.

Authors:  Madhav Sachar; Edward J Kelly; Jashvant D Unadkat
Journal:  AAPS J       Date:  2019-03-27       Impact factor: 4.009

8.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Authors:  J Andrew Williams; Barbara J Ring; Varon E Cantrell; David R Jones; James Eckstein; Kenneth Ruterbories; Mitchell A Hamman; Stephen D Hall; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2002-08       Impact factor: 3.922

Review 9.  Current best practice in the management of hypertensive disorders in pregnancy.

Authors:  Rosemary Townsend; Patrick O'Brien; Asma Khalil
Journal:  Integr Blood Press Control       Date:  2016-07-27

10.  Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy.

Authors:  Kwi Hye Koh; Steve Jurkovic; Kyunghee Yang; Su-Young Choi; Jin Woo Jung; Kwang Pyo Kim; Wei Zhang; Hyunyoung Jeong
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

View more
  3 in total

Review 1.  The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.

Authors:  Ian R Mulrenin; Julian E Garcia; Muluneh M Fashe; Matthew Shane Loop; Melissa A Daubert; Rachel Peragallo Urrutia; Craig R Lee
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-11       Impact factor: 4.481

2.  Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes.

Authors:  Raju Khatri; John K Fallon; Craig Sykes; Natasha Kulick; Rebecca J B Rementer; Taryn A Miner; Amanda P Schauer; Angela D M Kashuba; Kim A Boggess; Kim L R Brouwer; Philip C Smith; Craig R Lee
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

3.  Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes.

Authors:  Muluneh M Fashe; John K Fallon; Taryn A Miner; Jacqueline B Tiley; Philip C Smith; Craig R Lee
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.